QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

---

SCHEDULE TO
Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934

(Amendment No. 1)

---

ALERE INC.
(Name of Subject Company)

ABBOTT LABORATORIES
(Offeror)
(Names of Filing Persons)

SERIES B CONVERTIBLE PERPETUAL PREFERRED STOCK, $0.001 PAR VALUE
(Title of Class of Securities)

01449J204
(CUSIP Number of Class of Securities)

Hubert L. Allen
Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-6100
Telephone: (224) 667-6100
(Name, address, and telephone number of person authorized to receive notices
and communications on behalf of filing person)

---

Copies to:
Richard B. Aftanas, P.C.
Ross M. Leff
Kirkland & Ellis LLP
601 Lexington Avenue
New York, New York 10022
Telephone: (212) 446-4800

---

CALCULATION OF FILING FEE

*

Estimated for purposes of calculating the filing fee only. The transaction valuation was calculated by multiplying 1,774,407 shares of Series B Convertible Perpetual Preferred Stock, par value $0.001 per share (the "Preferred Stock"), of Alere Inc. ("Alere") outstanding by the offer price of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends due on the Preferred Stock. The transaction value is also based on an estimate of $2,720,757.40 of accrued but unpaid dividends on the Preferred Stock as of August 31, 2017.

**

The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for Fiscal Year 2017, issued August 31, 2016, by multiplying the Transaction Valuation by 0.0001159.

ý

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

o

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

ý

third-party tender offer subject to Rule 14d-1.



o

issuer tender offer subject to Rule 13e-4.



o

going-private transaction subject to Rule 13e-3.



o

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: o

   

---

        This Amendment No. 1 (this "Amendment") amends and supplements the Tender Offer Statement on Schedule TO initially filed with the United States Securities and Exchange Commission on July 17, 2017 (together with any amendments and supplements thereto, the "Schedule TO") relating to the offer by Abbott Laboratories, an Illinois corporation ("Abbott"), to purchase for cash all of the outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc., par value $0.001 per share (the "Preferred Stock"), at a purchase price of $402.00 per share of Preferred Stock (the "Offer Price"), plus accrued but unpaid dividends to, but not including, the settlement date of the Offer, net to the seller thereof in cash, without interest thereon and subject to any withholding taxes required by applicable law, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated as of July 17, 2017 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), and the related Letter of Transmittal (as it may be amended or supplemented from time to time, the "Letter of Transmittal," which, together with the Offer to Purchase, collectively constitute the "Offer"), copies of which are attached as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to the Schedule TO.

        All the information set forth in the Offer to Purchase, including Schedule I thereto, is incorporated herein by reference in response to Items 1 through 9 and Item 11 of the Schedule TO, except that such information is amended and supplemented to the extent specifically provided in this Amendment. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Offer to Purchase on in the Schedule TO.

Items 1, 4 and 11. Summary Term Sheet; Terms of the Transaction; Additional Information.

        Items 1, 4 and 11 of the Schedule TO are hereby amended and supplemented by adding the following text thereto:

        On August 14, 2017, Abbott announced an extension of the Offer to 11:59 p.m., New York City time, on August 31, 2017, unless the Offer is further extended or earlier terminated in accordance with the terms thereof. The Offer was previously scheduled to expire at 11:59 p.m., New York City time, on August 11, 2017.

        The Depositary has advised Abbott that, as of 11:59 p.m., New York City time, on August 11, 2017, greater than 90% of the issued and outstanding shares of Preferred Stock had been validly tendered pursuant to the Offer and not properly withdrawn.

        The full text of the press release issued by Abbott announcing the extension of the Offer is attached hereto as Exhibit (a)(5)(A) and is incorporated by reference herein.

        In addition, on August 21, 2017, Abbott sent holders the supplemental letter attached as Exhibit (a)(5)(B) hereto, which is incorporated by reference herein.

Item 12.    Exhibits

        Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibits:

Amendments to the Offer to Purchase and the Other Exhibits to the Schedule TO

        All references to "11:59 p.m., New York City time, on August 11, 2017" in the Offer to Purchase (Exhibit (a)(1)(A) to the Schedule TO), Letter of Transmittal (Exhibit (a)(1)(B) to the Schedule TO), Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (Exhibit (a)(1)(C) to the Schedule TO) and Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (Exhibit (a)(1)(D) to the Schedule TO) are hereby amended and replaced with "11:59 p.m., New York City time, on August 31, 2017". The Offer to Purchase and Items 1 through 9 and 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in any of the foregoing exhibits, are hereby amended and supplemented to reflect the same.

2

---

SIGNATURES

        After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 21, 2017

3

---

INDEX TO EXHIBITS

4

---

QuickLinks

Item 12. Exhibits

SIGNATURES
INDEX TO EXHIBITS





QuickLinks -- Click here to rapidly navigate through this document

Exhibit 99.(a)(5)(B)

Supplemental Letter to Holders Relating to the

Offer to Purchase for Cash
All Outstanding Shares of Series B Convertible Perpetual Preferred Stock

of

Alere Inc.

at

$402.00 Net Per Share of Series B Convertible Perpetual Preferred Stock

by

Abbott Laboratories

THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT
11:59 P.M., NEW YORK CITY TIME, ON AUGUST 31, 2017,
UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED
(SUCH DATE AND TIME, AS IT MAY BE EXTENDED OR EARLIER TERMINATED, THE "EXPIRATION DATE").

        As set forth in its Offer to Purchase, dated as of July 17, 2017 (the "Offer to Purchase"), Abbott Laboratories, an Illinois corporation ("Abbott," "we" or "us"), is offering to purchase all of the outstanding shares of Series B Convertible Perpetual Preferred Stock, par value $0.001 per share (the "Preferred Stock"), of Alere Inc., a Delaware corporation ("Alere"), issued pursuant to the Certificate of Designations, Preferences and Rights of Series B Convertible Perpetual Preferred Stock (the "Certificate of Designations"), at a price of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the Tender Settlement Date (as defined herein), net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law, upon the terms and subject to the conditions set forth in the Offer to Purchase (this "Offer").

        Abbott is providing this supplemental letter to holders of Preferred Stock to encourage holders to tender their shares of Preferred Stock in this Offer. Holders should review the Offer to Purchase, which contains all of the material terms and conditions of this Offer. This supplemental letter does not, and is not intended to, amend, alter, modify or otherwise change any of the terms of this Offer set forth in the Offer to Purchase, which, other than with respect to the extension of the Expiration Date described in the immediately preceding paragraph, remain unchanged.

        Abbott and Alere are party to an Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017, providing for the acquisition of Alere by Abbott (the "Merger"), with Alere surviving the Merger as a wholly-owned subsidiary of Abbott. The Merger is not conditioned upon, or otherwise subject to, the completion of this Offer. This Offer, however, is conditioned upon the consummation of the Merger.

        On August 14, 2017, Abbott announced that it had extended the Expiration Date of this Offer to 11:59 p.m., New York City time, on August 31, 2017 in order to allow additional time for the consummation of the Merger. American Stock Transfer & Trust Company, LLC, the depositary for this Offer, has advised Abbott that, as of 11:59 p.m., New York City time, on Friday, August 11, 2017, greater than 90% of the issued and outstanding shares of Preferred Stock had been tendered in this Offer.

---

SUMMARY OF KEY DATES & TERMS

* * * * *

What options are available to you in connection with the Merger and this Offer?

        You may:

1.

tender your shares of Preferred Stock to Abbott pursuant to the terms of this Offer;



2.

convert your shares of Preferred Stock in connection with the Merger pursuant to the terms of the Certificate of Designations; or



3.

retain your shares of Preferred Stock and continue to hold such shares following the consummation of the Merger.

        If you convert your shares of Preferred Stock in connection with the Merger, you may not separately tender such shares of Preferred Stock in this Offer.

How much is Abbott offering to pay for the shares of Preferred Stock and what is the form of payment? Will I have to pay any fees or commissions?

        Set forth below is a summary of the per-share consideration expected to be paid to you under each of the options noted above:

1.

If You Tender in this Offer: $402.00 per share plus accrued but unpaid dividends (liquidation preference of $400.00 per share, plus a premium of $2.00 per share)



2.

If You Convert in Connection with the Merger: maximum of $400.00 per share plus accrued but unpaid dividends



3.

If You Continue to Hold Shares of Preferred Stock: $294.29 per share plus accrued but unpaid dividends (only in limited circumstances and absent a subsequent Fundamental Change, as specified in the Certificate of Designations)

        If you are the record owner of your shares of Preferred Stock and you tender your shares of Preferred Stock to us in this Offer, you will not have to pay brokerage fees, commissions or similar expenses. If you own your shares of Preferred Stock through a broker or other nominee and your broker or other nominee tenders your shares of Preferred Stock on your behalf, your broker or nominee may charge a fee for doing so. You should consult your broker or nominee to determine whether any charges will apply. See Section 1—"Terms of the Offer" and Section 2—"Acceptance for Payment and Payment for Shares of Preferred Stock" of the Offer to Purchase for more information.

---

Who can you talk to if you have questions about this Offer?

        You may call D.F. King & Co., Inc., the Information Agent for this Offer, Toll-Free at (212) 269-5550 or (877) 283-0316, or Barclays Capital Inc., the Dealer-Manager for this Offer, Toll-Free at (212) 528-7581 or (800) 438-3242.

---

QuickLinks

Exhibit 99.(a)(5)(B)

Supplemental Letter to Holders Relating to the Offer to Purchase for Cash All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at $402.00 Net Per Share of Series B Convertible Perpetual Preferred Stock by Abbott Laboratories THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., NEW YORK CITY TIME, ON AUGUST 31, 2017, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED (SUCH DATE AND TIME, AS IT MAY BE EXTENDED OR EARLIER TERMINATED, THE "EXPIRATION DATE").
SUMMARY OF KEY DATES & TERMS